Clinical implications of antidepressant pharmacokinetics and pharmacogenetics

Annals of Pharmacotherapy

Volumn 30, Issue 12, 1996, Pages 1471-1479

  Cohen, Lawrence J ^a   Lindsay Devane, C ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYTOCHROME P450 ISOENZYME; DESIPRAMINE; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MICROSOME ENZYME; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENETICS; PHARMACOKINETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0030476715     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001216     Document Type: Article

References (90)

1. Depression Guideline Panel. Depression in primary care. Vol. 2. Treatment of major depression. Clinical Practice Guideline, Number 5. Rockville, MD: US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, April 1993. AHCPR Publication No. 93-0551.
2. Rudorfer MV, Lane EA, Chang WH, Zhang M, Potter WZ. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984;17:433-40.
3. Lin KM, Poland RE, Smith MW, Strickland TL, Mendoza R. Pharmacokinetic and other related factors affecting psychotropic responses in Asians. Psychopharmacol Bull 1991;27:427-39.
4. Alexanderson B, Evans DAP, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969;4:764-8.
5. Marinac JS, Foxworth JW, Willsie SK. Dextromethorphan polymorphic hepatic oxidation in healthy black American adult subjects. Ther Drug Monit 1995;17:120-4.
6. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou B, Liao C, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
7. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, et al. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985;38:402-8.
8. Hammer W, Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967;6:1895-903.
9. DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994;97(suppl 6A):13S-23S.
10. Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993;94(suppl 5A):2S-12S.
11. Product information. Luvox (fluvoxamine maleate). Marietta, GA: Solvay Pharmaceuticals, Inc., September 1995.
12. Product information. Serzone (nefazodone hydrochloride). Princeton, NJ: Bristol-Myers Squibb Company, January 1995.
13. Pentel PR, Bullock ML, DeVane CL. Hemoperfusion for imipramine overdose: elimination of active metabolites. J Toxicol Clin Toxicol 1982;19:239-48.
14. Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs 1991;41:2254-31.
15. Henry JA. Overdose and safety with fluvoxamine. Int Clin Psychopharmacol 1991;6(suppl 3):41-7.
16. Bickel MH, Graber BE, Moor M. Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. Life Sci 1983;33:2025-31.
17. MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:5-1-5-48.
18. McEvoy GK, ed. Tricyclic antidepressants general statement. In: AHFS drug information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1382-7.
19. Clark AM, Clinton RT, Baker JK, Hufford CD. Demethylation of imipramine by enteric bacteria. J Pharm Sci 1983;72:12288-90.
20. Lindenbaum J, Rund DG, Butler VP, Tse-Eng D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-94.
21. Sutfm TA, DeVane CL, Jusko WJ. The analysis and disposition of imipramine and its active metabolites. Psychopharmacology 1984;82:310-7.
22. DeVane CL, Jarecke CR. Cyclic antidepressants. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:33-1-33-47.
23. Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants - blood level measurements and clinical outcome. Am J Psychiatry 1985;142:155-62.
24. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20.
25. DeVane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53(2 suppl):13-20.
26. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Pharmacol 1993;71:1002-9.
27. Koe BK, Weissman A, Welch WM, Browne RG. Sertraline, 2S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin. J Pharmacol Exp Ther 1983;226:686-700.
28. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:278-87.
29. Sindrup SH, Brøsen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-95.
30. Hamelin BA, Turgeon J, Vallee F, Belanger PM, Paquet F, LeBel M. Role of CYP2D6 in the demethylation of fluoxetine in vivo (abstract). Clin Pharmacol Ther 1996;59:137.
31. Amsterdam JD, HornigRohan M, Rosenbaum JF, Quitkin FM, Fawcette J, Reimherr FW, et al. Fluoxetine and norfluoxetine plasma levels in major depression (abstract). Biol Psychiatry 1995;37:606.
32. Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK. Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Psychopharmacol 1993;8:25-9.
33. Tasker TC, Kay CM, Zussman BD, Link CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1989;350(suppl):152-5.
34. Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-94.
35. Prescribing Information. Wellbutrin (bupropion hydrochloride). In: Physicians' desk reference. 49th ed. Montvale, NJ: Medical Economics Data Production Company, 1995:824-7.
36. Laizure SC, DeVane CL, Stewan JT, Dommisse CS, Lai AA. Pharmacokinetics of bupropion and its major basic metabolites in normal volunteers. Clin Pharmacol Ther 1985;38:586-9.
37. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44:79-81.
38. Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS, et al. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995;15:327-33.
39. Golden RN, DeVane CL, Stewan JT, Dommisse CS, Lai AA. Pharmacokinetics of bupropion and its major basic metabolites in clinical outcome. Arch Gen Psychiatry 1985;45:145-9.
40. Preskorn SH. Should bupropion dosage be adjusted based upon therapeutic drug monitoring. Psychopharmacol Bull 1991;27:637-43.
41. Stefanini E, Fadda F, Medda L, Gessa GL. Selective inhibition of serotonin uptake by trazodone, a new antidepressant agent. Life Sci 1976;18:1459-66.
42. McEvoy GK, ed. Trazodone. In: AHFS drug information 94. Bethesda, MD: American Society of Hospital Pharmacists, 1994:1406-10.
43. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994;97(suppl 6A):24S-32S.
44. Li AA, Marek GJ, Hand TH, Seiden LS. Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine. Eur J Pharmacol 1990;177:137-44.
45. Klamerus KJ, Maloney K, Rudolph RL, Sisenwine SF, Jusko WJ, Chang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. S Clin Pharmacol 1992;32:616-24.
46. Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol 1993;16(suppl 3):S45-S50.
47. Von Moltke LL, Greenblatt DJ, Scheider J, Harmetz JS, Shader RI. Nefazodone in vitro: metabolic conversions and inhibition of P450-3A isoforms (abstract). Clin Pharmacol Ther 1996;59:176.
48. Sainati S, Shukla U, Chaikin P, Dockens R, Lasseter K. The single and multiple dose pharmacokinetics of nefazodone in healthy volunteers and subjects with hepatic impairment (abstract). J Clin Pharmacol 1992;32:756.
49. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 1994;26:59-70.
50. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry 1994:55(suppl):38-45.
51. Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuruyama Y, et al. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol 1991;10:1-14.
52. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
53. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction: an accidental finding (letter). Eur J Clin Pharmacol 1991;40:119-20.
54. Bloomer JC, Woods FR, Haddock RE, Lennard MS, Tucker GT. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992;33:521-3.
55. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
56. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors of cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
57. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 1995;15:409-16.
58. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995;15:399-408.
59. Grimsley SR, Jann MW, Carter JG, D'Mello AP, D'Souza MJ. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991;50:10-5.
60. Joblin M. Possible interaction of sertraline with carbamazepine (letter). N Z Med J 1994;107:43.
61. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P450 1A2 and P450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
62. Otton SV, Ball SE, Cheung SW, Inaba T, Sellers EM. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine and other 5HT uptake inhibitors (abstract). Clin Pharmacol Ther 1994;55:141.
63. Woods DJ, Coulter DM, Pillans P. Interaction of phenytoin and fluoxetine (letter). N Z Med J 1994;107:19.
64. Meyer UA, Zanger UM, Grant D, Blum M. Genetic polymorphisms of drug metabolism. Adv Drug Res 1990;19:197-214.
65. Campbell ME, Grant DM, Inaba T, Kalow L. Biotransformation of caffeine, paraxanthine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987;15:237-48.
66. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyzes O-demethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988;26:363-72.
67. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J, Schulz HU, Sjoqvist F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980;27:1673-7.
68. Skjelbo E, Gram LF, Brøsen K. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio): a population study. Br J Clin Pharmacol 1993;35:331-4.
69. Butler MA, Lang NP, Young JF, Caporoso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-7.
70. Daniels DG, Randolph C, Jaskiw G, Handel S, Williams T, Abi-Dargham A, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.
71. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
72. Pollock BG, Perel JM, Kirshner M, Altieri LP, Yeager AL, Reynolds CF III. S-mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 1991;40:609-11.
73. Skjelbo E, Brøsen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992;34:256-61.
74. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports (letter). J Neurol Neurosurg Psychiatry 1992;55:312-3.
75. Brøsen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990;1:220-39.
76. Brøsen K, Otton SV, Gram LF. Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 1985;57:357-60.
77. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev Psychiatry 1994;2:204-13.
78. Kronbach T, Matthys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
79. Popli AP, Baldessarini RJ, Cole JO. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1994;51:666-7.
80. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991;31:125-30.
81. Lan RM. Carbamazepine and sertraline (letter). N Z Med J 1994;107:209.
82. Andersen BB, Bikkelsen M, Vesterager A, Dam M, Kristensen HB, Pedersen B, et al. No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin. Epilepsy Res 1991;10:201-4.
83. Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants (letter). Am J Psychiatry 1988;145:1478.
84. Barros J, Asnis G. An interaction of sertraline and desipramine (letter). Am J Psychiatry 1993;150:1751 [correction 1994;151:300].
85. Härtter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 1993;110:302-8.
86. Alderman J, Greenblatt DJ, Allison J, Preskorn S, Harrison W, Chung M. Desipramine pharmacokinetics with the selective serotonin reuptake inhibitors (SSRIs), paroxertine or sertraline. Presented at the American Psychiatric Association Sesquicentennial Celebration, 1844-1994: Philadelphia, PA, May 21-26, 1994.
87. Zhi-Yi Z, Kaminsky LS. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 1995;50:205-11.
88. Van den Brekel AM, Harrington L. Toxic effects of theophylline caused by fluvoxamine. Can Med Assoc J 1994;151:9-10.
89. Zusstnan BD, Davie CC, Fowles E, Kumar R, Lang U, Wargenau M, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol 1995;39:539P-88P.
90. Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by